News & Analysis on Clinical Trial Services & Contract Research And Development
PEOPLE ON THE MOVE
By Melissa Fassbender
- Last updated on
Also this month, Synteract announced that Karl Deonanan has been named as the company’s new chief financial officer (CFO), joining the company from IQVIA, where he was CFO of the organization’s Research and Development Solutions segment.
In his new role, Deonanan will lead Synteract’s Finance and Contracts Proposals organizations.
“I am excited to be part of a passionate team that supports the development of pharmaceutical products which benefit patients around the world,” Deonanan told us.
“In this role, I look forward to working with the Synteract Executive team to build a growth strategy to position the Company as the premiere mid-size CRO – a CRO that is focused on supporting the needs of small and large pharmaceutical clients by leveraging our therapeutic expertise, operational capabilities and geographic reach.”